Eli Lilly and Company (NYSE: LLY) and Adocia (Euronext Paris: FR0011184241 – ADOC) today announced a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes. BioChaperone Lispro relies on Adocia’s proprietary BioChaperone® technology and is currently in Phase Ib studies.
Diabetes Health publisher Nadia Al-Samarrie spoke with television and movie actor Anthony Anderson, who has taken a lead role with Eli Lilly & Company's F.A.C.E. campaign, a diabetes outreach to African Americans. A veteran of more than 20 films, Anthony, age 41, currently plays Detective Kevin Bernard on NBC's Emmy Award-winning drama, "Law & Order."
I remember first seeing Kris Freeman when he was 21 at a diabetes conference. Two years after he was diagnosed with type 1 diabetes, Eli Lilly began sponsoring his dream of becoming an Olympic cross-country skier. During his off-season, you can find Kris at diabetes camps inspiring children to follow their dream. He is the only person with diabetes to compete in a winter endurance sports event at the Olympics.
Lilly Diabetes recently launched the free Lilly Glucagon Mobile App to educate those who support people living with type 1 diabetes. The interactive app, available on the iTunes store for iPhone and iPad devices, provides caregivers, diabetes educators, and school nurses with visual and audio emergency instructions, as well as tools to track locations of glucagon kits and alerts for expiration dates.
Boehringer Ingelheim Pharmaceuticals, Inc., and Eli Lilly and Company have introduced My Well Planner, a new online program offering customized educational content to help adults with type 2 diabetes make simple lifestyle changes to improve their health. Sample topics include general information about type 2 diabetes, better eating habits, building physical activity into daily life, taking medication, and communication strategies.
Boehringer Ingelheim and Eli Lilly have begun sales of Tradjenta, a drug for type 2 diabetes, in U.S. pharmacies. The drug (generic name linagliptin) comes in tablet form and is intended to compete with Amylin Pharmaceuticals' Byetta, which is injected, and Merck's Januvia, which also competes with Byetta. Both are well-established in the U.S. market.
French drug maker Sanofi-aventis says that results from a Phase III trial of its experimental type 2 diabetes drug lixisenatide show that the drug successfully lowered patients' blood glucose levels and body weight, but did not increase the risk of hypoglycemia.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health.
Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.